HCPCS Level II code J9177 denotes the injectable oncology drug enfortumab vedotin-ejfv, billed per 0.25 mg unit. This code is used to capture administration and acquisition costs for a targeted anticancer therapy delivered in outpatient infusion centers and oncology clinics. Nationally, biologic and specialty drug billing codes like J9177 matter because they drive specialty drug reporting, payer coverage determinations, and hospital and clinic reimbursement for high-cost oncology agents.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J9177 is positioned within billing workflows, typical sites of service, and what to expect in payer coverage patterns. The publication provides benchmarks for unit-based drug billing, notes common modifier usage where applicable, and summarizes clinical context for enfortumab vedotin-ejfv as an intravenous/subcutaneous injectable oncology agent.

This national-level summary is intended to help billing managers, revenue cycle staff, and policy analysts understand code use, payer relevance, and areas to review in claims processing and coverage policies. Data not available in the input are noted where specific payer rates, taxonomies, ICD-10 pairings, and related codes would normally be detailed.